NCT00271713View on ClinicalTrials.gov

Impact of Oral Ibandronate 150 mg Monthly on Structural Properties of Bone in Postmenopausal Osteoporosis (SPIMOS-3D)

PHASE4CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions
Osteoporosis, Postmenopausal
Interventions
DRUG

ibandronate, calcium and vitamin D

1: 150 mg ibandronate monthly plus 500mg calcium and 800 UI vitamin D daily or

DRUG

placebo,calcium and vitamin D

2: placebo monthly plus 500mg calcium and 800 UI vitamin D daily

Trial Locations (1)

12200

Centre for Muscle and Bone Research, Charité - Campus Benjamin Franklin, Berlin

All Listed Sponsors
lead

Charite University, Berlin, Germany

OTHER

NCT00271713 - Impact of Oral Ibandronate 150 mg Monthly on Structural Properties of Bone in Postmenopausal Osteoporosis (SPIMOS-3D) | Biotech Hunter | Biotech Hunter